Health and Human Services Secretary Robert F. Kennedy Jr. is working on identifying and tackling the root causes of America's obesity epidemic. In the meantime, the Trump administration wants to make sure that Americans have access to affordable diabetes and weight-loss drugs, specifically glucagon-like peptide-1 receptor agonists, better known as GLP-1 drugs .

To this end and as part of his months-long campaign to bring most-favored-nation prescription drug pricing to Americans, President Donald Trump has struck a deal with pharmaceutical giants Eli Lilly and Novo Nordisk, the manufacturer of Ozempic, to cut prices on their weight-loss drugs in exchange for Medicare coverage.

A senior administration official indicated on Thursday that since Trump issued his most-favored-nation

See Full Page